Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments
Increased capability to produce medicines for challenging diseases including cancer
Increased capability to produce medicines for challenging diseases including cancer
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Dr. Singh proposes upskilling medicos with AI, Quantum and other newer technologies to meet the changing requirements of patient care
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Advances Amgen's mission to serve patients with rare disease medicines
Subscribe To Our Newsletter & Stay Updated